查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1612251

製药业人工智慧市场：按产品、技术、部署模式、应用程式和最终用户划分 - 2025-2030 年全球预测

Artificial Intelligence in Pharmaceutical Market by Offering (Hardware, Services, Software), Technology (Computer Vision, Machine Learning, Natural Language Processing), Deployment Mode, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年人工智慧在製药市场的价值为125.8亿美元，预计到2024年将达到157.9亿美元，复合年增长率为26.68%，到2030年将达到659亿美元。

製药业中的人工智慧 (AI) 包括使用先进的演算法、机器学习和资料分析来加速药物发现、简化临床试验、个人化医疗和增强製造流程。对人工智慧的需求源自于製药业的大量资料和复杂性，需要创新的方法来提高效率、缩短上市时间并解决未满足的医疗需求。应用范围从疾病结果的预测建模和优化临床试验中的患者招募到自动化药物製造的重复任务。最终用途包括希望利用人工智慧获得竞争优势的製药公司、生物技术公司、研究机构和医疗保健提供者。关键的成长要素包括巨量资料可用性的不断提高和运算能力的进步，推动了对人工智慧分析庞大资料集并得出有意义的见解的需求。此外，随着专利到期和医疗保健成本的逼近，对具有成本效益的药物开发的需求不断增长，也推动了人工智慧的采用。扩大精准医疗、即时资料分析和改善病人参与平台的人工智慧能力存在机会。公司可以透过投资人才获取、建立策略联盟以及专注于道德人工智慧实施来利用这些优势。然而，挑战包括监管障碍、资料隐私问题以及将人工智慧系统整合到现有框架中的高成本。拥有人工智慧和製药专业知识的熟练专业人士也存在人才缺口。基于人工智慧的生物标记发现和用于虚拟模拟的数位双胞胎等创新具有突破的潜力。对人工智慧的道德使用的研究可以在保护患者资料的同时释放市场机会。製药人工智慧市场是动态的，经常受到监管政策、技术进步和协作研发工作的影响。为了在快速发展的环境中保持领先地位，公司需要保持敏捷性，拥抱开放创新模式和本土开发。

主要市场统计
基准年[2023] 125.8亿美元
预测年份 [2024] 157.9亿美元
预测年份 [2030] 659亿美元
复合年增长率（%） 26.68%

市场动态：揭示製药市场快速发展的人工智慧的关键市场洞察

供需的动态交互作用正在改变药品领域的人工智慧市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 对个人化医疗以改善治疗结果的需求不断增长
    • 利用人工智慧主导的方法来增强现有的药物再利用策略
    • 加强生物医学和临床资料处理的资料日益增长
  • 市场限制因素
    • 开发和引入人工智慧解决方案需要大量初始投资
  • 市场机会
    • 介绍针对製药业的人工智慧为基础的创新解决方案
    • 大力投资人工智慧药物发现研究
  • 市场挑战
    • 资料隐私和安全问题

波特五力：驾驭製药人工智慧市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对医药市场人工智慧的影响

外部宏观环境因素在塑造製药市场人工智慧的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解人工智慧药品市场的竞争状况

製药市场人工智慧的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 製药市场人工智慧定位矩阵供应商绩效评估

FPNV 定位矩阵是评估製药市场人工智慧供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

人工智慧在策略分析和药物推荐市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对製药市场人工智慧的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 对个人化医疗以改善治疗结果的需求不断增长
      • 利用人工智慧主导的方法来增强现有的药物再利用策略
      • 加强生物医学和临床资料处理的需求日益增长
    • 抑制因素
      • 开发和实施人工智慧解决方案需要大量初始投资
    • 机会
      • 介绍针对製药业的人工智慧为基础的创新解决方案
      • 大量投资人工智慧药物发现研究
    • 任务
      • 资料隐私和安全问题
  • 市场区隔分析
    • 我们提供什么：由于功能和能力的改进，基于人工智慧的软体的采用率有所提高
    • 技术：扩大机器学习技术在製药领域的应用
    • 应用：利用人工智慧解决方案简化临床试验流程
    • 最终用户：製药和生物技术公司大量采用人工智慧技术进行药物发现和开发
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 製药领域的人工智慧市场：透过提供

  • 硬体
    • 记忆
    • 网路
    • 处理器
  • 服务
    • 部署与集成
    • 支援与维护
  • 软体

第七章 製药领域的人工智慧市场：依技术分类

  • 电脑视觉
  • 机器学习
  • 自然语言处理
  • 机器人流程自动化

第八章 医药人工智慧市场：依部署模式

  • 云端基础的解决方案
    • 混合云端
    • 私有云端
    • 公共云端
  • 本地解决方案

第九章 製药领域的人工智慧市场：依应用分类

  • 临床试验
    • 临床资料管理
    • 病患招募
    • 安全监控
  • 医药开发
    • 配方开发
    • 临床前研究
    • 原型设计
  • 药物发现
    • 药物测试
    • 先导化合物识别和优化
  • 个人化医疗
    • 生物标记发现
    • 基因组分析
    • 病人的病程

第 10 章 製药业的人工智慧市场：依最终用户分类

  • 合约调查机构
  • 医疗服务提供方
  • 製药公司
  • 研究室

第十一章 美洲製药领域的人工智慧市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区医药人工智慧市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第13章：欧洲、中东和非洲製药业的人工智慧市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 赛诺菲、Formation Bio 和 OpenAI 合作透过人工智慧整合改变药物开发
    • NVIDIA BioNeMo 利用生成式 AI 模式转变药物发现，加速药物创新。
    • 丹麦与突破性的 NVIDIA超级电脑合作，引领製药领域的人工智慧创新
  • 战略分析和建议

公司名单

  • AiCure, LLC
  • Aspen Technology Inc.
  • Atomwise Inc.
  • BenevolentAI SA
  • BioSymetrics Inc.
  • BPGbio Inc.
  • Butterfly Network, Inc.
  • Cloud Pharmaceuticals, Inc.
  • Cyclica by Recursion Pharmaceuticals, Inc.
  • Deargen Inc.
  • Deep Genomics Incorporated
  • Deloitte Touche Tohmatsu Limited
  • Euretos Services BV
  • Exscientia PLC
  • Google LLC
  • Insilico Medicine
  • Intel Corporation
  • International Business Machines Corporation
  • InveniAI LLC
  • Isomorphic Labs Limited
  • Microsoft Corporation
  • Novo Nordisk A/S
  • NVIDIA Corporation
  • Oracle Corporation
  • SANOFI WINTHROP INDUSTRIE
  • Turbine Ltd.
  • Viseven Europe OU
  • XtalPi Inc.
Product Code: MRR-A6768A62EE00

The Artificial Intelligence in Pharmaceutical Market was valued at USD 12.58 billion in 2023, expected to reach USD 15.79 billion in 2024, and is projected to grow at a CAGR of 26.68%, to USD 65.90 billion by 2030.

Artificial Intelligence (AI) in the pharmaceutical industry encompasses the use of advanced algorithms, machine learning, and data analytics to accelerate drug discovery, streamline clinical trials, personalize medicine, and enhance manufacturing processes. The necessity for AI arises from the enormous data and complexity in pharmaceuticals, requiring innovative approaches to improve efficiency, reduce time-to-market, and address unmet medical needs. Applications range from predictive modeling of disease outcomes and optimizing patient recruitment for trials to automating repetitive tasks in drug manufacturing. End-use scope includes pharmaceutical companies, biotech firms, research institutions, and healthcare providers seeking to harness AI for competitive advantage. Key growth factors include the increasing availability of big data and advancements in computational power, driving demand for AI to analyze vast datasets for meaningful insights. Moreover, the rising need for cost-effective drug development in the face of looming patent expirations and healthcare costs further fuels AI adoption. Opportunities lie in expanding AI capabilities in precision medicine, real-time data analytics, and improving patient engagement platforms. Companies can capitalize on these by investing in talent acquisition, forming strategic alliances, and maintaining a focus on ethical AI deployment. However, challenges include regulatory hurdles, data privacy concerns, and high costs of integrating AI systems within existing frameworks. There's also a talent gap for skilled professionals adept in both AI and pharmaceuticals. Innovations in AI-driven biomarker discovery and digital twins for virtual simulations hold promise for breakthroughs. Research on ethical AI usage can safeguard patient data while unlocking market opportunity. The AI in pharmaceutical market is dynamic, often influenced by regulatory policies, technological advancements, and collaborative R&D efforts. Companies must remain agile, embracing both open innovation models and proprietary developments to stay ahead in a rapidly evolving landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 12.58 billion
Estimated Year [2024] USD 15.79 billion
Forecast Year [2030] USD 65.90 billion
CAGR (%) 26.68%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Artificial Intelligence in Pharmaceutical Market

The Artificial Intelligence in Pharmaceutical Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing demand for personalized medicine to improve treatment outcomes
    • Utilization of AI-driven approaches to enhance existing drug repurposing strategies
    • Increasing need to enhance the processing of biomedical and clinical data
  • Market Restraints
    • High initial investment for developing and implementing AI solutions
  • Market Opportunities
    • Introduction of innovative AI-based solutions for pharmaceutical industry
    • Significant investments for AI drug discovery research
  • Market Challenges
    • Concerns regarding data privacy and security

Porter's Five Forces: A Strategic Tool for Navigating the Artificial Intelligence in Pharmaceutical Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Artificial Intelligence in Pharmaceutical Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Artificial Intelligence in Pharmaceutical Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Artificial Intelligence in Pharmaceutical Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Artificial Intelligence in Pharmaceutical Market

A detailed market share analysis in the Artificial Intelligence in Pharmaceutical Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Artificial Intelligence in Pharmaceutical Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Artificial Intelligence in Pharmaceutical Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Artificial Intelligence in Pharmaceutical Market

A strategic analysis of the Artificial Intelligence in Pharmaceutical Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Artificial Intelligence in Pharmaceutical Market, highlighting leading vendors and their innovative profiles. These include AiCure, LLC, Aspen Technology Inc., Atomwise Inc., BenevolentAI SA, BioSymetrics Inc., BPGbio Inc., Butterfly Network, Inc., Cloud Pharmaceuticals, Inc., Cyclica by Recursion Pharmaceuticals, Inc., Deargen Inc., Deep Genomics Incorporated, Deloitte Touche Tohmatsu Limited, Euretos Services BV, Exscientia PLC, Google LLC, Insilico Medicine, Intel Corporation, International Business Machines Corporation, InveniAI LLC, Isomorphic Labs Limited, Microsoft Corporation, Novo Nordisk A/S, NVIDIA Corporation, Oracle Corporation, SANOFI WINTHROP INDUSTRIE, Turbine Ltd., Viseven Europe OU, and XtalPi Inc..

Market Segmentation & Coverage

This research report categorizes the Artificial Intelligence in Pharmaceutical Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Offering, market is studied across Hardware, Services, and Software. The Hardware is further studied across Memory, Network, and Processor. The Services is further studied across Deployment & Integration and Support & Maintenance.
  • Based on Technology, market is studied across Computer Vision, Machine Learning, Natural Language Processing, and Robotic Process Automation.
  • Based on Deployment Mode, market is studied across Cloud-Based Solutions and On-Premise Solutions. The Cloud-Based Solutions is further studied across Hybrid Cloud, Private Cloud, and Public Cloud.
  • Based on Application, market is studied across Clinical Trials, Drug Development, Drug Discovery, and Personalized Medicine. The Clinical Trials is further studied across Clinical Data Management, Patient Recruitment, and Safety Monitoring. The Drug Development is further studied across Formulation Development, Preclinical Studies, and Prototype Design. The Drug Discovery is further studied across Drug Screening and Lead Identification & Optimization. The Personalized Medicine is further studied across Biomarker Discovery, Genomic Analysis, and Patient Disease Journey.
  • Based on End User, market is studied across Contract Research Organizations, Healthcare Providers, Pharmaceutical Companies, and Research Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing demand for personalized medicine to improve treatment outcomes
      • 5.1.1.2. Utilization of AI-driven approaches to enhance existing drug repurposing strategies
      • 5.1.1.3. Increasing need to enhance the processing of biomedical and clinical data
    • 5.1.2. Restraints
      • 5.1.2.1. High initial investment for developing and implementing AI solutions
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of innovative AI-based solutions for pharmaceutical industry
      • 5.1.3.2. Significant investments for AI drug discovery research
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns regarding data privacy and security
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offerings: Growing AI-based software adoption owing to its improved functionality & features
    • 5.2.2. Technology: Increasing utilization of machine learning technology in the pharmaceutical sector
    • 5.2.3. Applications: Improving the efficiency of clinical trial process through AI solutions
    • 5.2.4. End-users: Significant implementation of AI technologies by pharma & biotech companies for drug discovery & development
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Artificial Intelligence in Pharmaceutical Market, by Offering

  • 6.1. Introduction
  • 6.2. Hardware
    • 6.2.1. Memory
    • 6.2.2. Network
    • 6.2.3. Processor
  • 6.3. Services
    • 6.3.1. Deployment & Integration
    • 6.3.2. Support & Maintenance
  • 6.4. Software

7. Artificial Intelligence in Pharmaceutical Market, by Technology

  • 7.1. Introduction
  • 7.2. Computer Vision
  • 7.3. Machine Learning
  • 7.4. Natural Language Processing
  • 7.5. Robotic Process Automation

8. Artificial Intelligence in Pharmaceutical Market, by Deployment Mode

  • 8.1. Introduction
  • 8.2. Cloud-Based Solutions
    • 8.2.1. Hybrid Cloud
    • 8.2.2. Private Cloud
    • 8.2.3. Public Cloud
  • 8.3. On-Premise Solutions

9. Artificial Intelligence in Pharmaceutical Market, by Application

  • 9.1. Introduction
  • 9.2. Clinical Trials
    • 9.2.1. Clinical Data Management
    • 9.2.2. Patient Recruitment
    • 9.2.3. Safety Monitoring
  • 9.3. Drug Development
    • 9.3.1. Formulation Development
    • 9.3.2. Preclinical Studies
    • 9.3.3. Prototype Design
  • 9.4. Drug Discovery
    • 9.4.1. Drug Screening
    • 9.4.2. Lead Identification & Optimization
  • 9.5. Personalized Medicine
    • 9.5.1. Biomarker Discovery
    • 9.5.2. Genomic Analysis
    • 9.5.3. Patient Disease Journey

10. Artificial Intelligence in Pharmaceutical Market, by End User

  • 10.1. Introduction
  • 10.2. Contract Research Organizations
  • 10.3. Healthcare Providers
  • 10.4. Pharmaceutical Companies
  • 10.5. Research Laboratories

11. Americas Artificial Intelligence in Pharmaceutical Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Artificial Intelligence in Pharmaceutical Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Artificial Intelligence in Pharmaceutical Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Sanofi, Formation Bio, and OpenAI collaborate to transform drug development through AI integration
    • 14.3.2. NVIDIA BioNeMo transforms drug discovery with generative AI models to accelerate pharmaceutical innovation
    • 14.3.3. Denmark pioneers AI innovation in pharmaceuticals with groundbreaking NVIDIA supercomputer collaboration
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AiCure, LLC
  • 2. Aspen Technology Inc.
  • 3. Atomwise Inc.
  • 4. BenevolentAI SA
  • 5. BioSymetrics Inc.
  • 6. BPGbio Inc.
  • 7. Butterfly Network, Inc.
  • 8. Cloud Pharmaceuticals, Inc.
  • 9. Cyclica by Recursion Pharmaceuticals, Inc.
  • 10. Deargen Inc.
  • 11. Deep Genomics Incorporated
  • 12. Deloitte Touche Tohmatsu Limited
  • 13. Euretos Services BV
  • 14. Exscientia PLC
  • 15. Google LLC
  • 16. Insilico Medicine
  • 17. Intel Corporation
  • 18. International Business Machines Corporation
  • 19. InveniAI LLC
  • 20. Isomorphic Labs Limited
  • 21. Microsoft Corporation
  • 22. Novo Nordisk A/S
  • 23. NVIDIA Corporation
  • 24. Oracle Corporation
  • 25. SANOFI WINTHROP INDUSTRIE
  • 26. Turbine Ltd.
  • 27. Viseven Europe OU
  • 28. XtalPi Inc.

LIST OF FIGURES

  • FIGURE 1. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET RESEARCH PROCESS
  • FIGURE 2. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET DYNAMICS
  • TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MEMORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NETWORK, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PROCESSOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT & INTEGRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPORT & MAINTENANCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPUTER VISION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HYBRID CLOUD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PRIVATE CLOUD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PUBLIC CLOUD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ON-PREMISE SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL DATA MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PATIENT RECRUITMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SAFETY MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PRECLINICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PROTOTYPE DESIGN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY GENOMIC ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PATIENT DISEASE JOURNEY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 201. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 202. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 212. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 213. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 222. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 224. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 225. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 227. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 234. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 235. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 236. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 237. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 250. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 251. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 256. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 258. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 259. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 260. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 261. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 262. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 263. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 268. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 270. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 271. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 272. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 273. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 274. VIETNAM ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 275. VIETNAM ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOU